Browse USP16

Summary
SymbolUSP16
Nameubiquitin specific peptidase 16
Aliases Ubp-M; ubiquitin specific protease 16; UBPM; deubiquitinating enzyme 16; ubiquitin thioesterase 16; ubiquiti ......
Chromosomal Location21q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus
Domain PF00443 Ubiquitin carboxyl-terminal hydrolase
PF02148 Zn-finger in ubiquitin-hydrolases and other protein
Function

Specifically deubiquitinates 'Lys-120' of histone H2A (H2AK119Ub), a specific tag for epigenetic transcriptional repression, thereby acting as a coactivator. Deubiquitination of histone H2A is a prerequisite for subsequent phosphorylation at 'Ser-11' of histone H3 (H3S10ph), and is required for chromosome segregation when cells enter into mitosis. In resting B- and T-lymphocytes, phosphorylation by AURKB leads to enhance its activity, thereby maintaining transcription in resting lymphocytes. Regulates Hox gene expression via histone H2A deubiquitination. Prefers nucleosomal substrates. Does not deubiquitinate histone H2B.

> Gene Ontology
 
Biological Process GO:0006414 translational elongation
GO:0006417 regulation of translation
GO:0006448 regulation of translational elongation
GO:0007067 mitotic nuclear division
GO:0010608 posttranscriptional regulation of gene expression
GO:0016570 histone modification
GO:0016578 histone deubiquitination
GO:0016579 protein deubiquitination
GO:0034248 regulation of cellular amide metabolic process
GO:0034250 positive regulation of cellular amide metabolic process
GO:0035520 monoubiquitinated protein deubiquitination
GO:0035521 monoubiquitinated histone deubiquitination
GO:0035522 monoubiquitinated histone H2A deubiquitination
GO:0045727 positive regulation of translation
GO:0045901 positive regulation of translational elongation
GO:0051259 protein oligomerization
GO:0051260 protein homooligomerization
GO:0051262 protein tetramerization
GO:0051289 protein homotetramerization
GO:0070536 protein K63-linked deubiquitination
GO:0070537 histone H2A K63-linked deubiquitination
GO:0070646 protein modification by small protein removal
Molecular Function GO:0003713 transcription coactivator activity
GO:0004175 endopeptidase activity
GO:0004197 cysteine-type endopeptidase activity
GO:0004843 thiol-dependent ubiquitin-specific protease activity
GO:0008234 cysteine-type peptidase activity
GO:0019783 ubiquitin-like protein-specific protease activity
GO:0032182 ubiquitin-like protein binding
GO:0036459 thiol-dependent ubiquitinyl hydrolase activity
GO:0042393 histone binding
GO:0043130 ubiquitin binding
GO:0101005 ubiquitinyl hydrolase activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-5688426: Deubiquitination
R-HSA-392499: Metabolism of proteins
R-HSA-597592: Post-translational protein modification
R-HSA-5689880: Ub-specific processing proteases
Summary
SymbolUSP16
Nameubiquitin specific peptidase 16
Aliases Ubp-M; ubiquitin specific protease 16; UBPM; deubiquitinating enzyme 16; ubiquitin thioesterase 16; ubiquiti ......
Chromosomal Location21q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between USP16 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolUSP16
Nameubiquitin specific peptidase 16
Aliases Ubp-M; ubiquitin specific protease 16; UBPM; deubiquitinating enzyme 16; ubiquitin thioesterase 16; ubiquiti ......
Chromosomal Location21q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of USP16 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolUSP16
Nameubiquitin specific peptidase 16
Aliases Ubp-M; ubiquitin specific protease 16; UBPM; deubiquitinating enzyme 16; ubiquitin thioesterase 16; ubiquiti ......
Chromosomal Location21q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of USP16 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.1440.638
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.4370.809
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.0720.958
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.1160.697
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.3160.88
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.1360.959
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0330.927
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.1360.937
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.1840.921
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.3460.778
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.8020.668
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0410.503
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of USP16 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277311.1011.10.0181
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275911.1011.10.0286
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolUSP16
Nameubiquitin specific peptidase 16
Aliases Ubp-M; ubiquitin specific protease 16; UBPM; deubiquitinating enzyme 16; ubiquitin thioesterase 16; ubiquiti ......
Chromosomal Location21q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of USP16. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolUSP16
Nameubiquitin specific peptidase 16
Aliases Ubp-M; ubiquitin specific protease 16; UBPM; deubiquitinating enzyme 16; ubiquitin thioesterase 16; ubiquiti ......
Chromosomal Location21q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of USP16. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by USP16.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolUSP16
Nameubiquitin specific peptidase 16
Aliases Ubp-M; ubiquitin specific protease 16; UBPM; deubiquitinating enzyme 16; ubiquitin thioesterase 16; ubiquiti ......
Chromosomal Location21q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of USP16. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolUSP16
Nameubiquitin specific peptidase 16
Aliases Ubp-M; ubiquitin specific protease 16; UBPM; deubiquitinating enzyme 16; ubiquitin thioesterase 16; ubiquiti ......
Chromosomal Location21q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of USP16 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolUSP16
Nameubiquitin specific peptidase 16
Aliases Ubp-M; ubiquitin specific protease 16; UBPM; deubiquitinating enzyme 16; ubiquitin thioesterase 16; ubiquiti ......
Chromosomal Location21q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between USP16 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolUSP16
Nameubiquitin specific peptidase 16
Aliases Ubp-M; ubiquitin specific protease 16; UBPM; deubiquitinating enzyme 16; ubiquitin thioesterase 16; ubiquiti ......
Chromosomal Location21q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting USP16 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.